Resistance to treatment in CML - Chronic myeloid leukemia
Primary Resistance
Non-adherence of CML patients
Food and Drug Interactions
Secondary Resistance
Detection of BCR-ABL1 mutations
JAK2 gene
Non-adherence of CML patients
Food and Drug Interactions
Secondary Resistance
Detection of BCR-ABL1 mutations
JAK2 gene
VIDEOS
Resistance to Targeted-TKI Treatment in Patients With CML
July 8, 2019, Targeted Oncology
Chronic Myeloid Leukemia: Understanding Loss of Response
August 20, 2018, OncLiveTV
Alternative Mechanism for Treatment of Resistant CML
January 20, 2017, OncLiveTV
Resistant Chronic Myeloid Leukemia (Patient testimonials)
June 19, 2015, Leukemia & Lymphoma Society
Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
February 24, 2014, OncLiveTV
Resistance to Targeted-TKI Treatment in Patients With CML
July 8, 2019, Targeted Oncology
Chronic Myeloid Leukemia: Understanding Loss of Response
August 20, 2018, OncLiveTV
Alternative Mechanism for Treatment of Resistant CML
January 20, 2017, OncLiveTV
Resistant Chronic Myeloid Leukemia (Patient testimonials)
June 19, 2015, Leukemia & Lymphoma Society
Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
February 24, 2014, OncLiveTV
ARTICLES
New combination treatment may overcome drug resistance in blood cancers
May 19, 2020, The University of British Columbia
Response and Resistance to BCR-ABL1-Targeted Therapies
April 13, 2020, Cancer Cell
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, PubMed
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
April 2019, Leukemia
OSU Research Paves Way for New Source for Leukemia Drug
March 20, 2019, The Skammer
The importance of mutational analysis in chronic myeloid leukemia
November 22, 2016, EMJ
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
February 18, 2016, Biomarker insights
Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
October 2011, Hematology/oncology clinics of North America
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
New combination treatment may overcome drug resistance in blood cancers
May 19, 2020, The University of British Columbia
Response and Resistance to BCR-ABL1-Targeted Therapies
April 13, 2020, Cancer Cell
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
April 7, 2020, PubMed
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
April 2019, Leukemia
OSU Research Paves Way for New Source for Leukemia Drug
March 20, 2019, The Skammer
The importance of mutational analysis in chronic myeloid leukemia
November 22, 2016, EMJ
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
February 18, 2016, Biomarker insights
Chronic Myeloid Leukemia – Mechanisms of Resistance and Treatment
October 2011, Hematology/oncology clinics of North America
Monitoring response and resistance to treatment in chronic myeloid leukemia
April 2011, Current Oncology
